CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials (Chinese version)

Journal of Chinese Integrative Medicine

Volumn 8, Issue 8, 2010, Pages 701-741

  Moher, David ^a   Hopewell, Sally ^b   Schulz, Kenneth F ^c   Montori, Victor ^d   Gøtzsche, Peter C ^e   Devereaux, P J ^f   Elbourne, Diana ^g   Egger, Matthias ^h   Altman, Douglas G ^b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c FAMILY HEALTH INTERNATIONAL   (United States)

^d MAYO CLINIC   (United States)

^e Rigshospitalet   (Denmark)

^f MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^h UNIVERSITY OF BERN   (Switzerland)

Author keywords

Clinical trials; CONSORT; Guidelines; Randomized controlled trials

Indexed keywords

INFORMATION PROCESSING; PRACTICE GUIDELINE; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 77956377420     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.3736/jcim20100801     Document Type: Review

References (313)

1. Rennie D. CONSORT revised - improving the reporting of randomized trials. JAMA. 2001; 285(15): 2006-2007. (Pubitemid 32366956)
2. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995; 273(5): 408-412.
3. Moher D. CONSORT: an evolving tool to help improve the quality of reports of randomized controlled trials. Consolidated Standards of Reporting Trials. JAMA. 1998; 279(18): 1489-1491.
4. Kjaergard LL, Villumsen J, Gluud C. Quality of randomised clinical trials affects estimates of intervention efficacy. 7th. Cochrane Colloquium. Rome. Italy. 1999.
5. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ. 2001; 323(7303): 42-46.
6. Veldhuyzen van Zanten SJ, Cleary C, Talley NJ, Peterson TC, Nyrén O, Bradley LA, Verlinden M, Tytgat GN. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol. 1996; 91(4): 660-673. (Pubitemid 26117940)
7. Talley NJ, Owen BK, Boyce P, Paterson K. Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. Am J Gastroenterol. 1996; 91(2): 277-283.
8. Adetugbo K, Williams H. How well are randomized controlled trials reported in the dermatology literature? Arch Dermatol. 2000; 136(3): 381-385.
9. Kjaergard LL, Nikolova D, Gluud C. Randomized clinical trials in HEPATOLOGY: predictors of quality. Hepatology. 1999; 30(5): 1134-1138. (Pubitemid 29510849)
10. Schor S, Karten I. Statistical evaluation of medical journal manuscripts. JAMA. 1966; 195(13): 1123-1128.
11. Gore SM, Jones IG, Rytter EC. Misuse of statistical methods: critical assessment of articles in BMJ from January to March 1976. Br Med J. 1977; 1(6053): 85-87.
12. Hall JC, Hill D, Watts JM. Misuse of statistical methods in the Australasian surgical literature. Aust N Z J Surg. 1982; 52(5): 541-543.
13. Altman DG. Statistics in medical journals. Stat Med. 1982; 1(1): 59-71.
14. Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials. A survey of three medical journals. N Engl J Med. 1987; 317(7): 426-432.
15. Altman DG. The scandal of poor medical research. BMJ. 1994; 308(6924): 283-284.
16. Chan AW, Altman DG. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet. 2005; 365(9465): 1159-1162.
17. Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG. The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ. 2010; 340: c723.
18. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ. 1999; 319(7211): 670-674.
19. Lai TY, Wong VW, Lam RF, Cheng AC, Lam DS, Leung GM. Quality of reporting of key methodological items of randomized controlled trials in clinical ophthalmic journals. Ophthalmic Epidemiol. 2007; 14 (6): 390-398.
20. Moher D, Fortin P, Jadad AR, Jüni P, Klassen T, Le Lorier J, Liberati A, Linde K, Penna A. Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet. 1996; 347(8998): 363-366.
21. Junker CA. Adherence to published standards of reporting: a comparison of placebo-controlled trials published in English or German. JAMA. 1998; 280 (3): 247-249.
22. Altman DG. Randomisation. BMJ. 1991; 302(6791): 1481-1482.
23. Schulz KF, Chalmers I, Grimes DA, Altman DG. Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. JAMA. 1994; 272(2): 125-128.
24. Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation. BMJ. 1948; 2: 769-782.
25. Schulz KF. Randomized controlled trials. Clin Obstet Gynecol. 1998; 41(2): 245-256.
26. Greenland S. Randomization, statistics, and causal inference. Epidemiology. 1990; 1(6): 421-429.
27. Armitage P. The role of randomization in clinical trials. Stat Med. 1982; 1(4): 345-352.
28. Kleijnen J, Gøtzsche PC, Kunz R, Oxman AD, Chalmers I. So what's so special about randomisation. In: Maynard A, Chalmers I, eds. Non-random reflections on health services research. BMJ Books. 1997: 93-106.
29. Chalmers I. Assembling comparison groups to assess the effects of health care. J R Soc Med. 1997; 90(7): 379-386.
30. Nicolucci A, Grilli R, Alexanian AA, Apolone G, Torri V, Liberati A. Quality, evolution, and clinical implications of randomized, controlled trials on the treatment of lung cancer. A lost opportunity for meta-analysis. JAMA. 1989; 262(15): 2101-2107.
31. Ah-See KW, Molony NC. A qualitative assessment of randomized controlled trials in otolaryngology. J Laryngol Otol. 1998; 112(5): 460-463. (Pubitemid 28271841)
32. Altman DG, Doré CJ. Randomisation and baseline comparisons in clinical trials. Lancet. 1990; 335(8682): 149-153.
33. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ. 1998; 317(7167): 1181-1184.
34. DerSimonian R, Charette LJ, McPeek B, Mosteller F. Reporting on methods in clinical trials. N Engl J Med. 1982; 306(22): 1332-1337.
35. A proposal for structured reporting of randomized controlled trials. The Standards of Reporting Trials Group. JAMA. 1994; 272(24): 1926-1931.
36. Call for comments on a proposal to improve reporting of clinical trials in the biomedical literature. Working Group on Recommendations for Reporting of Clinical Trials in the Biomedical Literature. Ann Intern Med. 1994; 121(11): 894-895.
37. Rennie D. Reporting randomized controlled trials. An experiment and a call for responses from readers. JAMA. 1995; 273(13): 1054-1055.
38. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA. 1996; 276(8): 637-639.
39. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006; 295(10): 1152-1160.
40. Campbell MK, Elbourne DR, Altman DG; CONSORT group. CONSORT statement: extension to cluster randomised trials. BMJ. 2004; 328(7441): 702-708.
41. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008; 337: a2390.
42. Ioannidis JP, Evans SJ, Gøtzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D; CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004; 141(10): 781-788.
43. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P; CONSORT Group. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med. 2008; 148(4): 295-309. (Pubitemid 351665487)
44. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C; CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann Intern Med. 2006; 144 (5): 364-367. (Pubitemid 46768190)
45. Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF; CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008; 5(1): e20.
46. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996; 276(16): 1339-1341.
47. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996; 313(7052): 275-283.
48. Lang TA , Secic M. How to report statistics in medicine. Annotated guidelines for authors, editors, and reviewers. ACP. 1997.
49. Davidoff F. News from the International Committee of Medical Journal Editors. Ann Intern Med. 2000; 133 (3): 229-231.
50. Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, Gaboury I. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust. 2006; 185 (5): 263-267.
51. Egger M, Jüni P, Bartlett C; CONSORT Group (Consolidated Standards of Reporting of Trials). Value of flow diagrams in reports of randomized controlled trials. JAMA. 2001; 285(15): 1996-1999. (Pubitemid 32366953)
52. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med. 2001; 134(8): 657-662. (Pubitemid 32322244)
53. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001; 285(15): 1987-1991. (Pubitemid 32366951)
54. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001; 357(9263): 1191-1194. (Pubitemid 32378696)
55. Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004; 291(20): 2457-2465.
56. Al-Marzouki S, Roberts I, Evans S, Marshall T. Selective reporting in clinical trials: analysis of trial protocols accepted by The Lancet. Lancet. 2008; 372(9634): 201.
57. Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, Cronin E, Decullier E, Easterbrook PJ, Von Elm E, Gamble C, Ghersi D, Ioannidis JP, Simes J, Williamson PR. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One. 2008; 3(8): e3081.
58. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T; CONSORT GROUP (Consolidated Standards of Reporting Trials). The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001; 134(8): 663-694. (Pubitemid 32322245)
59. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010; 11: 32.
60. Pocock SJ. Clinical trials: a practical approach. John Wiley. 1983.
61. Meinert CL. Clinical trials: design, conduct and analysis. Oxford University Press. 1986.
62. Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials. 3rd ed. Springer. 1998.
63. Bolliger CT, Zellweger JP, Danielsson T, van Biljon X, Robidou A, Westin A, Perruchoud AP, Säwe U. Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety. BMJ. 2000; 321(7257): 329-333.
64. Dickersin K, Manheimer E, Wieland S, Robinson KA, Lefebvre C, McDonald S. Development of the Cochrane Collaboration's CENTRAL Register of controlled clinical trials. Eval Health Prof. 2002; 25(1): 38-64. (Pubitemid 34157783)
65. Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF; CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008; 371(9609): 281-283.
66. The impact of open access upon public health. PLoS Med. 2006; 3(5): e252.
67. Harbourt AM, Knecht LS, Humphreys BL. Structured abstracts in MEDLINE, 1989-1991. Bull Med Libr Assoc. 1995; 83(2): 190-195.
68. Harris AH, Standard S, Brunning JL, Casey SL, Goldberg JH, Oliver L, Ito K, Marshall JM. The accuracy of abstracts in psychology journals. J Psychol. 2002; 136(2): 141-148.
69. Pitkin RM, Branagan MA, Burmeister LF. Accuracy of data in abstracts of published research articles. JAMA. 1999; 281(12): 1110-1111.
70. Ward LG, Kendrach MG, Price SO. Accuracy of abstracts for original research articles in pharmacy journals. Ann Pharmacother. 2004; 38(7-8): 1173-1177.
71. Gøtzsche PC. Believability of relative risks and odds ratios in abstracts: cross sectional study. BMJ. 2006; 333(7561): 231-234.
72. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001; 285(4): 437-443. (Pubitemid 32097262)
73. Haynes RB, Mulrow CD, Huth EJ, Altman DG, Gardner MJ. More informative abstracts revisited. Ann Intern Med. 1990; 113(1): 69-76.
74. Taddio A, Pain T, Fassos FF, Boon H, Ilersich AL, Einarson TR. Quality of nonstructured and structured abstracts of original research articles in the British Medical Journal, the Canadian Medical Association Journal and the Journal of the American Medical Association. CMAJ. 1994; 150(10): 1611-1615.
75. Wager E, Middleton P. Technical editing of research reports in biomedical journals. Cochrane Database Syst Rev. 2008. MR000002.
76. Hartley J, Sydes M, Blurton A. Obtaining information accurately and quickly: Are structured abstracts more efficient? J Inform Sci. 1996; 22(5): 349-356.
77. Gilligan D, Nicolson M, Smith I, Groen H, Dalesio O, Goldstraw P, Hatton M, Hopwood P, Manegold C, Schramel F, Smit H, van Meerbeeck J, Nankivell M, Parmar M, Pugh C, Stephens R. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet. 2007; 369(9577): 1929-1937.
78. Sandler AD, Sutton KA, DeWeese J, Girardi MA, Sheppard V, Bodfish JW. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med. 1999; 341(24): 1801-1806.
79. World Medical Association. Declaration of Helsinki: ethical principle for medical research involving human subjects. 59th WMA General Assembly, Seoul 2008; (accessed 2 June 2009).
80. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 1992; 327(4): 248-254.
81. Fergusson D, Glass KC, Hutton B, Shapiro S. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? Clin Trials. 2005; 2(3): 218-229.
82. Savulescu J, Chalmers I, Blunt J. Are research ethics committees behaving unethically? Some suggestions for improving performance and accountability. BMJ. 1996; 313(7069): 1390-1393. (Pubitemid 26400132)
83. Sadler LC, Davison T, McCowan LM. A randomised controlled trial and meta-analysis of active management of labour. BJOG. 2000; 107(7): 909-915.
84. Bath FJ, Owen VE, Bath PM. Quality of full and final publications reporting acute stroke trials: a systematic review. Stroke. 1998; 29(10): 2203-2210.
85. Blumer JL, Findling RL, Shih WJ, Soubrane C, Reed MD. Controlled clinical trial of zolpidem for the treatment of insomnia associated with attention-deficit/hyperactivity disorder in children 6 to 17 years of age. Pediatrics. 2009; 123(5): e770-e776.
86. Sabatine MS, Antman EM, Widimsky P, Ebrahim IO, Kiss RG, Saaiman A, Polasek R, Contant CF, McCabe CH, Braunwald E. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2009; 374(9692): 787-795.
87. Grant AM, Altman DG, Babiker AB, Campbell MK, Clemens FJ, Darbyshire JH, Elbourne DR, McLeer SK, Parmar MK, Pocock SJ, Spiegelhalter DJ, Sydes MR, Walker AE, Wallace SA; DAMOCLES study group. Issues in data monitoring and interim analysis of trials. Health Technol Assess. 2005; 9(7): 1-238, iii-iv.
88. Gallo P, Krams M. PhRMA Working Group on adaptive designs, "White Paper." Drug Inf J. 2006; 40(4): 421-482.
89. Brown CH, Ten Have TR, Jo B, Dagne G, Wyman PA, Muthen B, Gibbons RD. Adaptive designs for randomized trials in public health. Annu Rev Public Health. 2009; 30: 1-25.
90. Kelly PJ, Sooriyarachchi MR, Stallard N, Todd S. A practical comparison of group-sequential and adaptive designs. J Biopharm Stat. 2005; 15(4): 719-738.
91. Pildal J, Chan AW, Hróbjartsson A, Forfang E, Altman DG, Gøtzsche PC. Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study. BMJ. 2005; 330(7499): 1049.
92. Chan AW, Hróbjartsson A, Jørgensen KJ, Gøtzsche PC, Altman DG. Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. BMJ. 2008; 337: a2299.
93. Ndekha MJ, van Oosterhout JJ, Zijlstra EE, Manary M, Saloojee H, Manary MJ. Supplementary feeding with either ready-to-use fortified spread or corn-soy blend in wasted adults starting antiretroviral therapy in Malawi: randomised, investigator blinded, controlled trial. BMJ. 2009; 338: b1867.
94. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?" Lancet. 2005. 365(9453): 82-93.
95. Fuks A, Weijer C, Freedman B, Shapiro S, Skrutkowska M, Riaz A. A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group. J Clin Epidemiol. 1998; 51(2): 69-79.
96. Shapiro SH, Weijer C, Freedman B. Reporting the study populations of clinical trials. Clear transmission or static on the line? J Clin Epidemiol. 2000; 53(10): 973-979.
97. Gandhi M, Ameli N, Bacchetti P, Sharp GB, French AL, Young M, Gange SJ, Anastos K, Holman S, Levine A, Greenblatt RM. Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS. 2005; 19(16): 1885-1896.
98. Hall JC, Mills B, Nguyen H, Hall JL. Methodologic standards in surgical trials. Surgery. 1996; 119(4): 466-472.
99. Weiss NS, Koepsell TD, Psaty BM. Generalizability of the results of randomized trials. Arch Intern Med. 2008; 168(2): 133-135.
100. POISE Study Group, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, Xavier D, Chrolavicius S, Greenspan L, Pogue J, Pais P, Liu L, Xu S, Málaga G, Avezum A, Chan M, Montori VM, Jacka M, Choi P. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008; 371(9627): 1839-1847.
101. Rannou F, Dimet J, Boutron I, Baron G, Fayad F, Macé Y, Beaudreuil J, Richette P, Ravaud P, Revel M, Poiraudeau S. Splint for base-of-thumb osteoarthritis: a randomized trial. Ann Intern Med. 2009; 150(10): 661-669.
102. Glasziou P, Meats E, Heneghan C, Shepperd S. What is missing from descriptions of treatment in trials and reviews? BMJ. 2008; 336(7659): 1472-1474.
103. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000; 356(9227): 385-390. (Pubitemid 30487495)
104. McDowell I, Newell C. Measuring health: a guide to rating scales and questionnaires. 3rd ed. New York: Oxford University Press. 2006.
105. Streiner D, Norman C. Health measurement scales: a practical guide to their development and use. 3rd ed. Oxford: Oxford University Press. 2003.
106. Clarke M. Standardising outcomes for clinical trials and systematic reviews. Trials. 2007; 8: 39.
107. Sanders C, Egger M, Donovan J, Tallon D, Frankel S. Reporting on quality of life in randomised controlled trials: bibliographic study. BMJ. 1998; 317(7167): 1191-1194. (Pubitemid 28488508)
108. Gøtzsche PC. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Control Clin Trials. 1989; 10(1): 31-56.
109. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. Br J Psychiatry. 2000; 176: 249-252.
110. Jadad AR, Boyle M, Cunnigham C, Kim M, Schachar R. Treatment of Attention-Deficit/Hyperactivity Disorder. Evidence Report/Technology Assessment No. 11. Rockville, MD: U. S. Department of Health and Human Services, Public Health Service, Agency for Healthcare Research and Quality. AHQR publication No. 00-E005. 1999.
111. Schachter HM, Pham B, King J, Langford S, Moher D. The efficacy and safety of methylphenidate in attention deficit disorder: A systematic review and meta-analyis. Prepared for the Therapeutics Initiative, Vancouver, B. C., and the British Columbia Ministry for Children and Families. 2000.
112. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001; 357(9266): 1385-1390. (Pubitemid 32455364)
113. Chan AW, Krleza-Jeriĉ K, Schmid I, Altman DG. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ. 2004; 171(7): 735-740.
114. Vermeulen H, Hofland J, Legemate DA, Ubbink DT. Intravenous fluid restriction after major abdominal surgery: a randomized blinded clinical trial. Trials. 2009; 10: 50.
115. Fox K, Ford I, Steg PG, Tendera M, Ferrari R; BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372(9641): 807-816.
116. Campbell MJ, Julious SA, Altman DG. Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. BMJ. 1995; 311(7013): 1145-1148.
117. Guyatt GH, Mills EJ, Elbourne D. In the era of systematic reviews, does the size of an individual trial still matter. PLoS Med. 2008; 5(1): e4.
118. Schulz KF, Grimes DA. Sample size calculations in randomised trials: mandatory and mystical. Lancet. 2005; 365(9467): 1348-1353. (Pubitemid 40501299)
119. Halpern SD, Karlawish JH, Berlin JA. The continuing unethical conduct of underpowered clinical trials. JAMA. 2002; 288(3): 358-362.
120. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ. 1995; 311(7003): 485.
121. Moher D, Dulberg CS, Wells GA. Statistical power, sample size, and their reporting in randomized controlled trials. JAMA. 1994; 272(2): 122-124. (Pubitemid 24206043)
122. Freiman JA, Chalmers TC, Smith H Jr, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. N Engl J Med. 1978; 299(13): 690-694.
123. Charles P, Giraudeau B, Dechartres A, Baron G, Ravaud P. Reporting of sample size calculation in randomised controlled trials: review. BMJ. 2009; 338: b1732.
124. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stat Med. 1984; 3(4): 409-422.
125. Goodman SN, Berlin JA. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med. 1994; 121(3): 200-206.
126. Galgiani JN, Catanzaro A, Cloud GA, Johnson RH, Williams PL, Mirels LF, Nassar F, Lutz JE, Stevens DA, Sharkey PK, Singh VR, Larsen RA, Delgado KL, Flanigan C, Rinaldi MG. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med. 2000; 133(9): 676-686.
127. Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009; 360(20): 2066-2078.
128. Geller NL, Pocock SJ. Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners. Biometrics. 1987; 43(1): 213-223. (Pubitemid 17063905)
129. Berry DA. Interim analyses in clinical trials: classical vs. Bayesian approaches. Stat Med. 1985; 4(4): 521-526.
130. Pocock SJ. When to stop a clinical trial. BMJ. 1992; 305(6847): 235-240.
131. DeMets DL, Pocock SJ, Julian DG. The agonising negative trend in monitoring of clinical trials. Lancet. 1999; 354(9194): 1983-1988.
132. Buyse M. Interim analyses, stopping rules and data monitoring in clinical trials in Europe. Stat Med. 1993; 12(5-6): 509-520. (Pubitemid 23119070)
133. Sydes MR, Altman DG, Babiker AB, Parmar MK, Spiegelhalter DJ; DAMOCLES Group. Reported use of data monitoring committees in the main published reports of randomized controlled trials: a cross-sectional study. Clin Trials. 2004; 1(1): 48-59.
134. Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, Lacchetti C, Leung TW, Darling E, Bryant DM, Bucher HC, Schünemann HJ, Meade MO, Cook DJ, Erwin PJ, Sood A, Sood R, Lo B, Thompson CA, Zhou Q, Mills E, Guyatt GH. Randomized trials stopped early for benefit: a systematic review. JAMA. 2005; 294(17): 2203-2209.
135. Coutinho IC, Ramos de Amorim MM, Katz L, Bandeira de Ferraz AA. Uterine exteriorization compared with in situ repair at cesarean delivery: a randomized controlled trial. Obstet Gynecol. 2008; 111(3): 639-647.
136. Jüni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. In: Egger M, Davey Smith G, Altman DG, eds. Systematic reviews in health care: meta-analysis in context. BMJ Books. 2001.
137. Creinin MD, Meyn LA, Borgatta L, Barnhart K, Jensen J, Burke AE, Westhoff C, Gilliam M, Dutton C, Ballagh SA. Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial. Obstet Gynecol. 2008; 111(2 pt 1): 267-277.
138. Tate DF, Jackvony EH, Wing RR. Effects of internet behavioral counseling on weight loss in adults at risk for type 2 diabetes: a randomized trial. JAMA. 2003; 289(14): 1833-1836.
139. Lachin JM. Properties of simple randomization in clinical trials. Control Clin Trials. 1988; 9(4): 312-326.
140. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976; 34(6): 585-612.
141. Schulz KF, Grimes DA. The Lancet handbook of essential concepts in clinical research. Elsevier. 2006.
142. Altman DG, Bland JM. How to randomise. BMJ. 1999; 319(7211): 703-704.
143. Schulz KF. Subverting randomization in controlled trials. JAMA. 1995; 274(18): 1456-1458.
144. Enas GG, Enas NH, Spradlin CT, Wilson MG, Wiltse CG. Baseline comparability in clinical trials: prevention of poststudy anxiety. Drug Inf J. 1990; 24: 541-548.
145. Treasure T, MacRae KD. Minimisation: the platinum standard for trials? Randomisation doesn't guarantee similarity of groups; minimisation does. BMJ. 1998; 317(7155): 362-363.
146. Sinei SK, Schulz KF, Lamptey PR, Grimes DA, Mali JK, Rosenthal SM, Rosenberg MJ, Riara G, Njage PN, Bhullar VB, Ogembo HV. Preventing IUCD-related pelvic infection: the efficacy of prophylactic doxycycline at insertion. Br J Obstet Gynaecol. 1990; 97(5): 412-419.
147. Radford JA, Landorf KB, Buchbinder R, Cook C. Effectiveness of low-Dye taping for the short-term treatment of plantar heel pain: a randomised trial. BMC Musculoskelet Disord. 2006; 7: 64.
148. Chalmers TC, Levin H, Sacks HS, Reitman D, Berrier J, Nagalingam R. Meta-analysis of clinical trials as a scientific discipline. I: Control of bias and comparison with large co-operative trials. Stat Med. 1987; 6(3): 315-328.
149. Pocock SJ. Statistical aspects of clinical trial design. Statistician. 1982; 31(1): 1-18.
150. Haag U. Technologies for automating randomized treatment assignment in clinical trials. Drug Inf J. 1998; 32: 11.
151. Piaggio G, Elbourne D, Schulz KF, Villar J, Pinol AP, Gülmezoglu AM; WHO Research Group to evaluate Misoprostol in the Management of the Third Stage of Labour. The reporting of methods for reducing and detecting bias: an example from the WHO Misoprostol Third Stage of Labour equivalence randomised controlled trial. BMC Med Res Methodol. 2003; 3: 19.
152. Pildal J, Hróbjartsson A, Jórgensen KJ, Hilden J, Altman DG, Gøtzsche PC. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. Int J Epidemiol. 2007; 36(4): 847-857.
153. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, Gluud C, Martin RM, Wood AJ, Sterne J A. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008; 336(7644): 601-605.
154. McCandlish R, Bowler U, van Asten H, Berridge G, Winter C, Sames L, Garcia J, Renfrew M, Elbourne D. A randomised controlled trial of care of the perineum during second stage of normal labour. Br J Obstet Gynaecol. 1998; 105(12): 1262-1272.
155. Webster J, Clarke S, Paterson D, Hutton A, van Dyk S, Gale C, Hopkins T. Routine care of peripheral intravenous catheters versus clinically indicated replacement: randomised controlled trial. BMJ. 2008; 337: a339.
156. Smith SA, Shah ND, Bryant SC, Christianson TJ, Bjornsen SS, Giesler PD, Krause K, Erwin PJ, Montori VM; Evidens Research Group. Chronic care model and shared care in diabetes: randomized trial of an electronic decision support system. Mayo Clin Proc. 2008; 83(7): 747-757.
157. Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, McManus K, Champagne CM, Bishop LM, Laranjo N, Leboff MS, Rood JC, de Jonge L, Greenway FL, Loria CM, Obarzanek E, Williamson DA. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009; 360(9): 859-873.
158. Kaptchuk TJ . Intentional ignorance: a history of blind assessment and placebo controls in medicine. Bull Hist Med. 1998; 72(3): 389-433.
159. Guyatt GH, Pugsley SO, Sullivan MJ, Thompson PJ, Berman L, Jones NL, Fallen EL, Taylor DW. Effect of encouragement on walking test performance. Thorax. 1984; 39(11): 818-822.
160. Gøtzsche PC. Blinding during data analysis and writing of manuscripts. Control Clin Trials. 1996; 17(4): 285-290.
161. Karlowski TR, Chalmers TC, Frenkel LD, Kapikian AZ, Lewis TL, Lynch JM. Ascorbic acid for the common cold. A prophylactic and therapeutic trial. JAMA. 1975; 231(10): 1038-1042.
162. Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology. 1994; 44(1): 16-20.
163. Carley SD, Libetta C, Flavin B, Butler J, Tong N, Sammy I. An open prospective randomised trial to reduce the pain of blood glucose testing: ear versus thumb. BMJ. 2000; 321(7252): 20.
164. Schulz KF, Chalmers I, Altman DG. The landscape and lexicon of blinding in randomized trials. Ann Intern Med. 2002; 136(3): 254-259.
165. Day SJ, Altman DG. Statistics notes: blinding in clinical trials and other studies. BMJ. 2000; 321(7259): 504.
166. Montori VM, Bhandari M, Devereaux PJ, Manns BJ, Ghali WA, Guyatt GH. In the dark: the reporting of blinding status in randomized controlled trials. J Clin Epidemiol. 2002; 55(8): 787-790.
167. Cheng K, Smyth RL, Motley J, O'Hea U, Ashby D. Randomized controlled trials in cystic fibrosis (1966-1997) categorized by time, design, and intervention. Pediatr Pulmonol. 2000; 29(1): 1-7.
168. Lang T. Masking or blinding? An unscientific survey of mostly medical journal editors on the great debate. Med Gen Med. 2000; 2(1): E25.
169. Devereaux PJ, Manns BJ, Ghali WA, Quan H, Lacchetti C, Montori VM, Bhandari M, Guyatt GH. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA. 2001; 285(15): 2000-2003.
170. Haahr MT, Hróbjartsson A. Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors. Clin Trials. 2006; 3(4): 360-365.
171. Meinert CL. Masked monitoring in clinical trials - blind stupidity? N Engl J Med. 1998; 338(19): 1381-1382.
172. Mills E, Prousky J, Raskin G, Gagnier J, Rachlis B, Montori VM, Juurlink D. The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]. BMC Clin Pharmacol. 2003; 3: 4.
173. Schulz KF, Grimes DA, Altman DG, Hayes RJ. Blinding and exclusions after allocation in randomised controlled trials: survey of published parallel group trials in obstetrics and gynaecology. BMJ. 1996; 312(7033): 742-744.
174. Fergusson D, Glass KC, Waring D, Shapiro S. Turning a blind eye: the success of blinding reported in a random sample of randomised, placebo controlled trials. BMJ. 2004; 328(7437): 432.
175. Sackett DL. Turning a blind eye: why we don't test for blindness at the end of our trials. BMJ. 2004; 328(7448): 1136.
176. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009; 374(9701): 1606-1616.
177. Altman DG, Gore SM, Gardner MJ, Pocock SJ. Statistical guidelines for contributors to medical journals. In: Altman DG, Machin D, Bryant TN, Gardner MJ, eds. Statistics with confidence: confidence intervals and statistical guidelines. 2nd ed. BMJ Books. 2000: 171-190.
178. Altman DG, Bland JM. Statistics notes. Units of analysis. BMJ. 1997; 314(7098): 1874.
179. Bolton S. Independence and statistical inference in clinical trial designs: a tutorial review. J Clin Pharmacol. 1998; 38(5): 408-412.
180. Greenland S. Principles of multilevel modelling. Int J Epidemiol. 2000; 29(1): 158-167.
181. Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, Buring JE, Manson JE. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008; 299(17): 2027-2036.
182. Matthews JN, Altman DG. Interaction 3: How to examine heterogeneity. BMJ. 1996; 313(7061): 862.
183. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000; 355(9209): 1064-1069.
184. Matthews JN, Altman DG. Statistics notes. Interaction 2: Compare effect sizes not P values. BMJ. 1996; 313(7060): 808.
185. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med. 1992; 116(1): 78-84.
186. Steyerberg EW, Bossuyt PM, Lee KL. Clinical trials in acute myocardial infarction: should we adjust for baseline characteristics? Am Heart J. 2000; 139(5): 745-751.
187. Altman DG. Adjustment for covariate imbalance. In: Armitage P, Colton T, eds. Encyclopedia of biostatistics. John Wiley. 1998: 1000-1005.
188. Mülliner M, Matthews H, Altman DG. Reporting on statistical methods to adjust for confounding: a cross-sectional survey. Ann Intern Med. 2002; 136(2): 122-126.
189. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med. 1993; 118(3): 201-210.
190. Bender R, Grouven U. Logistic regression models used in medical research are poorly presented. BMJ. 1996; 313(7057): 628.
191. Khan KS, Chien PF, Dwarakanath LS. Logistic regression models in obstetrics and gynecology literature. Obstet Gynecol. 1999; 93(6): 1014-1020.
192. Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med. 1979; 301(26): 1410-1412.
193. May GS, DeMets DL, Friedman LM, Furberg C, Passamani E. The randomized clinical trial: bias in analysis. Circulation. 1981; 64(4): 669-673.
194. Altman DG, Cuzick J, Peto J. More on zidovudine in asymptomatic HIV infection. N Engl J Med. 1994; 330(24): 1758-1759.
195. Meinert CL. Beyond CONSORT: need for improved reporting standards for clinical trials. Consolidated Standards of Reporting Trials. JAMA. 1998; 279(18): 1487-1489.
196. Grant AM, Wileman SM, Ramsay CR, Mowat NA, Krukowski ZH, Heading RC, Thursz MR, Campbell MK; REFLUX Trial Group. Minimal access surgery compared with medical management for chronic gastrooesophageal reflux disease: UK collaborative randomised trial. BMJ. 2008; 337: a2664.
197. van Loon AJ, Mantingh A, Serlier EK, Kroon G, Mooyaart EL, Huisjes HJ. Randomised controlled trial of magnetic-resonance pelvimetry in breech presentation at term. Lancet. 1997; 350(9094): 1799-1804.
198. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000; 356(9227): 366-372.
199. LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000; 133(7): 516-526.
200. Shuster JJ. Median follow-up in clinical trials. J Clin Oncol. 1991; 9(1): 191-192.
201. Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. Br J Cancer. 1995; 72(2): 511-518.
202. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005; 2(11): e298.
203. Diggle L, Deeks J. Effect of needle length on incidence of local reactions to routine immunisation in infants aged 4 months: randomised controlled trial. BMJ. 2000; 321(7266): 931-933.
204. Pocock S, White I. Trials stopped early: too good to be true? Lancet. 1999; 353(9157): 943-944.
205. Hughes MD, Pocock SJ. Stopping rules and estimation problems in clinical trials. Stat Med. 1988; 7(12): 1231-1242.
206. Kiri A, Tonascia S, Meinert CL. Treatment effects monitoring committees and early stopping in large clinical trials. Clin Trials. 2004; 1(1): 40-47.
207. Psaty BM, Rennie D. Stopping medical research to save money: a broken pact with researchers and patients. JAMA. 2003; 289(16): 2128-2131.
208. Temple R. FDA perspective on trials with interim efficacy evaluations. Stat Med. 2006; 25(19): 3245-3249.
209. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008; 372(9644): 1174-1183.
210. Senn S. Base logic: tests of baseline balance in randomized clinical trials. Clin Res Regul Aff. 1995; 12(3): 171-182.
211. Altman DG. Comparability of randomised groups. Statistician. 1985; 34(1): 125-136.
212. Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000; 132(11): 853-861.
213. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology. 2000; 119(3): 639-646.
214. Fields WS, Maslenikov V, Meyer JS, Hass WK, Remington RD, Macdonald M. Joint study of extracranial arterial occlusion. V. Progress report of prognosis following surgery or nonsurgical treatment for transient cerebral ischemic attacks and cervical carotid artery lesions. JAMA. 1970; 211(12): 1993-2003.
215. Lee YJ, Ellenberg JH, Hirtz DG, Nelson KB. Analysis of clinical trials by treatment actually received: is it really an option? Stat Med. 1991; 10(10): 1595-1605.
216. Lewis JA, Machin D. Intention to treat - who should use ITT? Br J Cancer. 1993; 68(4): 647-650.
217. Lachin JL. Statistical considerations in the intent-to-treat principle. Control Clin Trials. 2000; 21(5): 526.
218. Sheiner LB, Rubin DB. Intention-to-treat analysis and the goals of clinical trials. Clin Pharmacol Ther. 1995; 57(1): 6-15.
219. Nagelkerke N, Fidler V, Bernsen R, Borgdorff M. Estimating treatment effects in randomized clinical trials in the presence of non-compliance. Stat Med. 2000; 19(14): 1849-1864.
220. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003; 326(7400): 1171-1173.
221. Gravel J, Opatrny L, Shapiro S. The intention-to-treat approach in randomized controlled trials: are authors saying what they do and doing what they say? Clin Trials. 2007; 4(4): 350-356.
222. Kruse RL, Alper BS, Reust C, Stevermer JJ, Shannon S, Williams RH. Intention-to-treat analysis: who is in? Who is out? J Fam Pract. 2002; 51(11): 969-971.
223. Herman A, Botser IB, Tenenbaum S, Chechick A. Intention-to-treat analysis and accounting for missing data in orthopaedic randomized clinical trials. J Bone Joint Surg Am. 2009; 91(9): 2137-2143.
224. Ruiz-Canela M, Martínez-González MA, de Irala-Estévez J. Intention to treat analysis is related to methodological quality. BMJ. 2000; 320(7240): 1007-1008.
225. Altman DG. Missing outcomes in randomized trials: addressing the dilemma. Open Med. 2009; 3(2): e51-53.
226. Wood AM, White IR, Thompson SG. Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals. Clin Trials. 2004; 1(4): 368-376.
227. Streiner DL. Missing data and the trouble with LOCF. Evid Based Ment Health. 2008; 11(1): 3-5.
228. Molnar FJ, Hutton B, Fergusson D. Does analysis using "last observation carried forward" introduce bias in dementia research? CMAJ. 2008; 179(8): 751-753.
229. Ware JH. Interpreting incomplete data in studies of diet and weight loss. N Engl J Med. 2003; 348(21): 2136-2137.
230. Streiner DL. The case of the missing data: methods of dealing with dropouts and other research vagaries. Can J Psychiatry. 2002; 47(1): 68-75.
231. Lane P. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm Stat. 2008; 7(2): 93-106.
232. Abraha I, Montedori A, Romagnoli C. Modified intention to treat: frequency, definition and implication for clinical trials [abstract]. Sao Paulo, Brazil: XV Cochrane Colloquium. 2007: 86-87.
233. Altman DG. Confidence intervals in practice. In: Altman DG, Machin D, Bryant TN, Gardner MJ, eds. Statistics with confidence. 2nd ed. BMJ Books. 2000: 6-14.
234. van Linschoten R, van Middelkoop M, Berger MY, Heintjes EM, Verhaar JA, Willemsen SP, Koes BW, Bierma-Zeinstra SM. Supervised exercise therapy versus usual care for patellofemoral pain syndrome: an open label randomised controlled trial. BMJ. 2009; 339: b4074.
235. Altman DG. Clinical trials and meta-analyses. In: Altman DG, Machin D, Bryant TN, Gardner MJ, eds. Statistics with confidence. 2nd ed. BMJ Books. 2000: 120-138.
236. Uniform requirements for manuscripts submitted to biomedical journals. International Committee of Medical Journal Editors. Ann Intern Med. 1997; 126(1): 36-47.
237. Gardner MJ, Altman DG. Confidence intervals rather than P values: estimation rather than hypothesis testing. BMJ. 1986; 292(6522): 746-750.
238. Bailar JC 3rd, Mosteller F. Guidelines for statistical reporting in articles for medical journals. Amplifications and explanations. Ann Intern Med. 1988; 108(2): 266-273.
239. Bland JM. Quoting intermediate analyses can only mislead. BMJ. 1997; 314(7098): 1907-1908.
240. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995; 310(6977): 452-454.
241. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999; 319(7223): 1492-1495.
242. The OSIRIS Collaborative Group. Early versus delayed neonatal administration of a synthetic surfactant - the judgment of OSIRIS (open study of infants at high risk of or with respiratory insufficiency - the role of surfactant). Lancet. 1992; 340(8832): 1363-1369.
243. Sorensen L, Gyrd-Hansen D, Kristiansen IS, Nexøe J, Nielsen JB. Laypersons' understanding of relative risk reductions: randomised cross-sectional study. BMC Med Inform Decis Mak. 2008; 8: 31.
244. Bobbio M, Demichelis B, Giustetto G. Completeness of reporting trial results: effect on physicians' willingness to prescribe. Lancet. 1994; 343(8907): 1209-1211.
245. Naylor CD, Chen E, Strauss B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med. 1992; 117(11): 916-921.
246. Tukey JW. Some thoughts on clinical trials, especially problems of multiplicity. Science. 1977; 198(4318): 679-684.
247. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991; 266(1): 93-98.
248. Hahn S, Williamson PR, Hutton JL, Garner P, Flynn EV. Assessing the potential for bias in meta-analysis due to selective reporting of subgroup analyses within studies. Stat Med. 2000; 19(24): 3325-3336.
249. Bhandari M, Devereaux PJ, Li P, Mah D, Lim K, Schnemann HJ, Tornetta P 3rd. Misuse of baseline comparison tests and subgroup analyses in surgical trials. Clin Orthop Relat Res. 2006; 447: 247-251.
250. Levin M, Quint PA, Goldstein B, Barton P, Bradley JS, Shemie SD, Yeh T, Kim SS, Cafaro DP, Scannon PJ , Giroir BP. Recombinant bactericidal/ permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet. 2000; 356(9234): 961-967.
251. Scharf O, Colevas AD. Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol. 2006; 24(24): 3933-3938.
252. Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med. 2009; 169(19): 1756-1761.
253. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007; 356(15): 1503-1516.
254. Horton R. The rhetoric of research. BMJ. 1995; 310(6985): 985-987.
255. Annals of Internal Medicine. Information for authors. Available at www.annals.org (accessed 15 Jan 2008).
256. Docherty M, Smith R. The case for structuring the discussion of scientific papers. BMJ. 1999; 318(7193): 1224-1225.
257. Purcell GP, Donovan SL, Davidoff F. Changes to manuscripts during the editorial process: characterizing the evolution of a clinical paper. JAMA. 1998; 280(3): 227-228.
258. Ioannidis JP. Limitations are not properly acknowledged in the scientific literature. J Clin Epidemiol. 2007; 60(4): 324-329.
259. Kiviluoto T, Sirén J, Luukkonen P, Kivilaakso E. Randomised trial of laparoscopic versus open cholecystectomy for acute and gangrenous cholecystitis. Lancet. 1998; 351(9099): 321-325.
260. Hupperets MD, Verhagen EA, van Mechelen W. Effect of unsupervised home based proprioceptive training on recurrences of ankle sprain: randomised controlled trial. BMJ. 2009; 339: b2684.
261. Garber J, Clarke GN, Weersing VR, Beardslee WR, Brent DA, Gladstone TR, DeBar LL, Lynch FL, D'Angelo E, Hollon SD, Shamseddeen W, Iyengar S. Prevention of depression in at-risk adolescents: a randomized controlled trial. JAMA. 2009; 301(21): 2215-2224.
262. CAMPBELL DT. Factors relevant to the validity of experiments in social settings. Psychol Bull. 1957; 54(4): 297-312.
263. Rothwell PM. Factors that can affect the external validity of randomised controlled trials. PLoS Clin Trials. 2006; 1(1): e9.
264. King M, Nazareth I, Lampe F, Bower P, Chandler M, Morou M, Sibbald B, Lai R. Conceptual framework and systematic review of the effects of participants' and professionals' preferences in randomised controlled trials. Health Technol Assess. 2005; 9(35): 1-186, iii-iv.
265. Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, Kuderer NM, Lyman GH. The uncertainty principle and industry-sponsored research. Lancet. 2000; 356(9230): 635-638.
266. Dans AL, Dans LF, Guyatt GH, Richardson S. Users' guides to the medical literature: XIV. How to decide on the applicability of clinical trial results to your patient. Evidence-Based Medicine Working Group. JAMA. 1998; 279(7): 545-549.
267. Smith GD, Egger M. Who benefits from medical interventions? BMJ. 1994; 308(6921): 72-74.
268. McAlister FA. Applying the results of systematic reviews at the bedside. In: Egger M, Davey Smith G, Altman DG, eds. Systematic reviews in health care: meta-analysis in context. BMJ Books. 2001.
269. Bartlett C, Doyal L, Ebrahim S, Davey P, Bachmann M, Egger M, Dieppe P. The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess. 2005; 9(38): iii-iv, ix-x, 1-152.
270. Bonell C, Oakley A, Hargreaves J, Strange V, Rees R. Assessment of generalisability in trials of health interventions: suggested framework and systematic review. BMJ. 2006; 333(7563): 346-349.
271. Bornhöft G, Maxion-Bergemann S, Wolf U, Kienle GS, Michalsen A, Vollmar HC, Gilbertson S, Matthiessen PF. Checklist for the qualitative evaluation of clinical studies with particular focus on external validity and model validity. BMC Med Res Methodol. 2006; 6: 56.
272. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988; 318(26): 1728-1733.
273. Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998; 317(7168): 1309-1312.
274. Fanaroff AA, Korones SB, Wright LL, Wright EC, Poland RL, Bauer CB, Tyson JE, Philips JB 3rd, Edwards W, Lucey JF, Catz CS, Shankaran S, Oh W; National Institute of Child Health and Human Development Neonatal Research Network. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. N Engl J Med. 1994; 330(16): 1107-1113.
275. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet. 1986; 2(8498): 57-66.
276. Gøtzsche PC, Gjørup I, Bonnén H, Brahe NE, Becker U, Burcharth F. Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis. BMJ. 1995; 310(6993): 1495-1498.
277. Clarke M, Hopewell S, Chalmers I. Reports of clinical trials should begin and end with up-to-date systematic reviews of other relevant evidence: a status report. J R Soc Med. 2007; 100(4): 187-190.
278. Goodman SN. Toward evidence-based medical statistics. 1: The P value fallacy. Ann Intern Med. 1999; 130(12): 995-1004.
279. Gøtzsche PC. Reference bias in reports of drug trials. BMJ. 1987; 295(6599): 654-656.
280. Papp K, Bissonnette R, Rosoph L, Wasel N, Lynde CW, Searles G, Shear NH, Huizinga RB, Maksymowych WP. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet. 2008; 371(9621): 1337-1342.
281. Dickersin K. How important is publication bias? A synthesis of available data. AIDS Educ Prev. 1997; 9(1 Suppl): 15-21.
282. Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ. Publication and related biases. Health Technol Assess. 2000; 4(10): 1-115.
283. Williamson PR, Gamble C. Identification and impact of outcome selection bias in meta-analysis. Stat Med. 2005; 24(10): 1547-1561.
284. Tramèr MR, Reynolds DJ, Moore RA, McQuay HJ. Impact of covert duplicate publication on meta-analysis: a case study. BMJ. 1997; 315(7109): 635-640.
285. Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol. 1986; 4(10): 1529-1541.
286. Chalmers I. From optimism to disillusion about commitment to transparency in the medico-industrial complex. J R Soc Med. 2006; 99(7): 337-341.
287. Tonks A. A clinical trials register for Europe. BMJ. 2002; 325(7376): 1314-1315.
288. Dickersin K, Rennie D. Registering clinical trials. JAMA. 2003; 290(4): 516-523.
289. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet. 2004; 363(9418): 1341-1345.
290. De Angelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJ, Schroeder TV, Sox HC, Van Der Weyden MB; International Committee of Medical Journal Editors. Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. Lancet. 2005; 365(9474): 1827-1829.
291. Zarin DA, Ide NC, Tse T, Harlan WR, West JC, Lindberg DA. Issues in the registration of clinical trials. JAMA. 2007; 297(19): 2112-2120.
292. Hopewell S, Altman DG, Moher D, Schulz KF. Endorsement of the CONSORT Statement by high impact factor medical journals: a survey of journal editors and journal 'Instructions to Authors'. Trials. 2008; 9: 20.
293. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D; VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008; 358(9): 877-887.
294. Chan AW, Tetzlaff J, Altman D, Gøtzsche PC, Hróbjartsson A, Krleza-Jeric K, et al. The SPIRIT initiative: defining standard protocol items for randomised trials. Oral presentation at the 16th Cochrane Colloquium: Evidence in the era of globalisation; 2008 Oct 3-7; Freiburg, Germany [abstract]. Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen 2008; 102: 27.
295. Gregson S, Adamson S, Papaya S, Mundondo J, Nyamukapa CA, Mason PR, Garnett GP, Chandiwana SK, Foster G, Anderson RM. Impact and process evaluation of integrated community and clinic-based HIV-1 control: a cluster-randomised trial in eastern Zimbabwe. PLoS Med. 2007; 4(3): e102.
296. Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, Ross RD, Pahl E, Blume ED, Dodd DA, Rosenthal DN, Burr J, LaSalle B, Holubkov R, Lukas MA, Tani LY; Pediatric Carvedilol Study Group. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA. 2007; 298(10): 1171-1179.
297. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003; 326(7400): 1167-1170.
298. Kjaergard LL, Als-Nielsen B. Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ. BMJ. 2002; 325(7358): 249.
299. Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med. 2007; 4(6): e184.
300. Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials. 2008; 29(2): 109-113.
301. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA. 2003; 290(7): 921-928.
302. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. 2008; 299(15): 1800-1812.
303. McAlister FA, Straus SE, Sackett DL, Altman DG. Analysis and reporting of factorial trials: a systematic review. JAMA. 2003; 289(19): 2545-2553.
304. Senn S. Crossover trials in clinical research. 2nd ed. Wiley. 2002.
305. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, Petticrew M, Altman DG; International Stroke Trial Collaborative Group; European Carotid Surgery Trial Collaborative Group. Evaluating non-randomised intervention studies. Health Technol Assess. 2003; 7(27): iii-x, 1-173.
306. Kunz R, Vist G, Oxman AD. Randomisation to protect against selection bias in healthcare trials. Cochrane Database Syst Rev 2007. MR000012.
307. Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet. 2001; 357(9253): 373-380.
308. Schulz KF. Randomised trials, human nature, and reporting guidelines. Lancet. 1996; 348(9027): 596-598.
309. Murray GD. Promoting good research practice. Stat Methods Med Res. 2000; 9(1): 17-24.
310. Narahari SR, Ryan TJ, Aggithaya MG, Bose KS, Prasanna KS. Evidence-based approaches for the Ayurvedic traditional herbal formulations: toward an Ayurvedic CONSORT model. J Altern Complement Med. 2008; 14(6): 769-776.
311. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HCW. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Ann Intern Med. 2003; 138(1): 40-44.
312. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007; 147(8): 573-577.
313. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van't Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009; 360(3): 213-224.